Eliem Therapeutics (ELYM) Competitors $2.40 +0.02 (+0.84%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. ALEC, PBYI, LXEO, VOR, DBVT, RNAC, ALLO, JBIO, FENC, and IMMPShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Alector (ALEC), Puma Biotechnology (PBYI), Lexeo Therapeutics (LXEO), Vor Biopharma (VOR), DBV Technologies (DBVT), Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Adherex Technologies (FENC), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Alector Puma Biotechnology Lexeo Therapeutics Vor Biopharma DBV Technologies Cartesian Therapeutics Allogene Therapeutics Jade Biosciences Adherex Technologies Prima BioMed Eliem Therapeutics (NASDAQ:ELYM) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Which has more volatility and risk, ELYM or ALEC? Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Which has higher valuation and earnings, ELYM or ALEC? Eliem Therapeutics has higher earnings, but lower revenue than Alector. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-4.53Alector$100.56M2.83-$119.05M-$1.16-2.43 Does the media prefer ELYM or ALEC? In the previous week, Alector had 6 more articles in the media than Eliem Therapeutics. MarketBeat recorded 6 mentions for Alector and 0 mentions for Eliem Therapeutics. Alector's average media sentiment score of 1.47 beat Eliem Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the news media. Company Overall Sentiment Eliem Therapeutics Neutral Alector Positive Do institutionals & insiders believe in ELYM or ALEC? 69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 9.7% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ELYM or ALEC more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Alector's net margin of -142.10%. Eliem Therapeutics' return on equity of -47.03% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Alector -142.10%-112.06%-26.37% Do analysts prefer ELYM or ALEC? Alector has a consensus target price of $4.17, indicating a potential upside of 48.02%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29 SummaryAlector beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.41M$873.44M$5.82B$10.17BDividend YieldN/A4.84%5.69%4.60%P/E Ratio-4.531.1474.6725.98Price / SalesN/A27.05454.5485.61Price / CashN/A19.5637.0859.91Price / Book0.626.8012.186.31Net Income-$35.12M-$4.20M$3.29B$270.86M7 Day Performance3.00%8.71%1.08%3.46%1 Month Performance45.45%11.25%7.32%6.57%1 Year Performance-70.00%25.29%63.11%28.39% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$2.40+0.8%N/A-69.8%$71.41MN/A-4.539ALECAlector3.9566 of 5 stars$2.61+10.9%$4.17+59.9%-50.6%$263.65M$100.56M-2.25270Positive NewsPBYIPuma Biotechnology4.0139 of 5 stars$5.16+2.3%$7.00+35.7%+80.0%$260.67M$230.50M5.28200Positive NewsLXEOLexeo Therapeutics2.7246 of 5 stars$4.79-0.1%$15.33+220.4%-49.4%$259.36M$650K-1.4758Positive NewsVORVor Biopharma2.3191 of 5 stars$2.03+2.8%$6.07+199.6%+71.2%$256.53MN/A-1.23140News CoverageInsider TradeDBVTDBV Technologies2.855 of 5 stars$9.34-3.2%$14.75+57.9%+157.7%$255.69M$4.15M-1.9680News CoverageShort Interest ↑Gap DownRNACCartesian Therapeutics2.4689 of 5 stars$9.82-2.3%$40.00+307.3%-35.8%$255.32M$38.91M-0.1964ALLOAllogene Therapeutics3.0519 of 5 stars$1.14+0.4%$8.44+644.0%-59.8%$254.05M$20K-1.03310JBIOJade Biosciences2.7276 of 5 stars$7.78-1.5%$16.00+105.7%N/A$253.86MN/A-0.2620FENCAdherex Technologies2.5604 of 5 stars$8.93+0.7%$13.33+49.2%+71.7%$247.37M$47.54M-21.1810IMMPPrima BioMed1.4566 of 5 stars$1.65+2.2%$7.00+325.5%-35.9%$241.47M$5.14M0.002,021News Coverage Related Companies and Tools Related Companies Alector Alternatives Puma Biotechnology Alternatives Lexeo Therapeutics Alternatives Vor Biopharma Alternatives DBV Technologies Alternatives Cartesian Therapeutics Alternatives Allogene Therapeutics Alternatives Jade Biosciences Alternatives Adherex Technologies Alternatives Prima BioMed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts